Optimind Pharma

Optimind Pharma Liabilities

The The Liabilities of Optimind Pharma (OMND.CN) as of Nov 4, 2026 is 329,515.00 CAD. In the previous year, The Liabilities was 274,963.00 CAD — a change of 19.84% (higher).

Liabilities

329,515.00CAD

YoY

19.84%

Last updated:

In 2026, Optimind Pharma's total liabilities amounted to 329,515.00 CAD, a 19.84% difference from the 274,963.00 CAD total liabilities in the previous year.

The Optimind Pharma Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
1.13 M CAD
Jan 1, 2019
1.10 M CAD
Jan 1, 2020
92,500.00 CAD
Jan 1, 2021
200,200.00 CAD
Jan 1, 2023
714,578.00 CAD
Jan 1, 2024
367,199.00 CAD
Jan 1, 2025
274,963.00 CAD
Jan 1, 2026
329,515.00 CAD
The Optimind Pharma Liabilities history
YEARLiabilitiesYoY
329,515.00CAD+19.84%
274,963.00CAD-25.12%
367,199.00CAD-48.61%
714,578.00CAD+256.93%
200,200.00CAD+116.43%
92,500.00CAD-91.57%
1.10 MCAD-3.03%
1.13 MCAD+32.32%
855,500.00CAD-27.19%
1.17 MCAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Optimind Pharma Stock analysis

What does Optimind Pharma do? Optimind Pharma Corp. generates revenue through medical cannabis and ketamine-assisted treatments for mental health conditions including PTSD, anxiety, and depression. The company offers two treatment types: Monotherapy and assisted therapy, both utilizing ketamine capsules. These programs integrate psychedelic medicine with therapeutic processing, based on scientific research and established therapeutic modalities. The firm partners with psilocybin treatment developers to expand its offerings, targeting patients seeking alternative mental health solutions through psychedelic-enhanced psychotherapy. Optimind Pharma Corp.'s primary customers are individuals suffering from mental illnesses and disabilities, particularly those with PTSD, anxiety, and depression. The company's treatment programs are designed to restore cognitive function within two hours of ketamine capsule administration, appealing to patients seeking rapid therapeutic effects. By combining ketamine with therapeutic integration, the firm addresses a growing market demand for innovative mental health treatments beyond conventional pharmaceuticals. The company's revenue streams include direct patient treatment services and partnerships with psilocybin-associated treatment developers. These partnerships allow Optimind to offer expanded program options without developing new products internally. The focus on scientifically backed psychedelic-enhanced psychotherapy differentiates Optimind in the mental health treatment sector, targeting patients who prefer non-traditional approaches to managing mental health conditions. Optimind Pharma is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Optimind Pharma's Liabilities

Optimind Pharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Optimind Pharma's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Optimind Pharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Optimind Pharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Optimind Pharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Optimind Pharma stock

The Liabilities of Optimind Pharma is 329,515.00 CAD in 2026.

The Liabilities of Optimind Pharma changed from 274,963.00 CAD to 329,515.00 CAD, representing a 19.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Optimind Pharma since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Optimind Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Optimind Pharma

All Key Metrics — Optimind Pharma